Catalytica Pharmaceuticals Signs New Agreement With Warner-lambert.MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--June 17, 1999-- Catalytica Pharmaceuticals, Inc., a subsidiary of Catalytica, Inc. (Nasdaq:CTAL CTAL Confederacion de Trabajadores de America Latina (Confederation of Latin American Workers) CTAL Canadian Tire Acceptance Limited CTAL Computer Technology Application Lab, Inc. CTAL Confidentially Typed Assembly Language ), announced today that it has entered into a new agreement with Warner-Lambert to produce consumer healthcare products at its pharmaceutical manufacturing operations Manufacturing operations concern the operation of a facility, as opposed to maintenance, supply and distribution, health, and safety, emergency response, human resources, security, information technology and other infrastructural support organizations. in Greenville, NC. Under the terms of the agreement, Warner-Lambert and Catalytica will undertake certain activities to prepare Catalytica's pharmaceutical production facility for the manufacture and packaging of Zantac(R)75, a non-prescription strength advanced medicine for the relief of heartburn heartburn, burning sensation beneath the breastbone, also called pyrosis. Heartburn does not indicate heart malfunction but results from nervous tension or overindulgence in food or drink. , acid indigestion acid indigestion n. 1. Indigestion that results from an excess of hydrochloric acid in the stomach. 2. Heartburn. Acid indigestion Indigestion that results from too much acid in the stomach. and sour stomach. The two companies are currently negotiating a definitive manufacturing and supply agreement which will stipulate stip·u·late 1 v. stip·u·lat·ed, stip·u·lat·ing, stip·u·lates v.tr. 1. a. To lay down as a condition of an agreement; require by contract. b. that Catalytica will be the exclusive supplier of Zantac(R)75 for the U.S. and Canadian markets. "This start-up agreement enables Catalytica to prepare for the manufacture of Zantac(R)75, an important product for Warner-Lambert. We believe this commitment by Warner-Lambert conveys their confidence in our manufacturing and packaging capabilities. We are committed to ensure that our performance meets their needs at the highest level," said Dr. Gabriel Cipau, President and Chief Executive Officer of Catalytica Pharmaceuticals. Catalytica Pharmaceuticals, Inc., a subsidiary of Catalytica, Inc., provides the pharmaceutical and biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. industries with comprehensive skills and demonstrated commercial experience in a broad spectrum of areas extending from process development through drug development, formulation, manufacturing and packaging. Since the acquisition of the Greenville Facility from Glaxo Wellcome in 1997, Catalytica has entered into over 25 new agreements for the development and manufacture of products for various pharmaceutical and biotech companies. In anticipation of additional business, it has expanded its chemical manufacturing facility and is currently expanding its sterile facility. It is the largest independent, fully integrated drug development and manufacturing supplier in the world. Catalytica, Inc. builds businesses in high growth industries where the Company's technologies optimize manufacturing and solve environmental problems. Catalytica Pharmaceuticals, Inc. provides drug development and product manufacturing to the pharmaceutical industry; Catalytica Combustion Systems, Inc. produces XONON, a catalytic system that permits essentially pollution free combustion for the energy market; and Catalytica Advanced Technologies, Inc. serves as the incubator incubator, apparatus for the maintenance of controlled conditions in which eggs can be hatched artificially. Incubator houses with double walls of mud, a fireroom, and several compartments each holding about 6,000 hens' eggs were developed in ancient times; the for new catalytic technologies for industrial applications. Find Catalytica on the World Wide Web at www.catalytica-inc.com This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. regarding Catalytica's future manufacturing and/or packaging of products for Warner-Lambert at the Greenville, North Carolina
Greenville, one of the fastest growing cities in North Carolina, is the county seat of Pitt County, and is the principal city of the Greenville, North Carolina Metropolitan Statistical Area. facility, the ability to obtain new business, the success of recently announced agreements and contracts, and of ongoing development contracts, the ability to market the Company's development, manufacturing and other services to current and prospective clients, and Catalytica's competitive position in its markets. These statements involve risks and uncertainties, including without limitation, the ability to operate the development, manufacturing, and packaging facilities efficiently, the ability to perform cost effectively and in a timely manner, the potential for product development delays, changes in the Company's competitive position, and the impact of FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulations on pharmaceutical and biotech manufacturing. Investors are encouraged to review Catalytica's Form 10K for the year ending December 31, 1998 for a more complete discussion of risk factors that could affect Catalytica's future performance. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion